These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 23150701)

  • 21. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
    Shitara K; Yuki S; Yamazaki K; Naito Y; Fukushima H; Komatsu Y; Yasui H; Takano T; Muro K
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):595-603. PubMed ID: 23250506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
    Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
    Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
    Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
    J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
    Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
    J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
    Figueras J; Lopez-Ben S; Alsina M; Soriano J; Hernandez-Yagüe X; Albiol M; Guardeño R; Codina-Barreras A; Queralt B
    Clin Transl Oncol; 2013 Jun; 15(6):460-6. PubMed ID: 23143951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
    Chan KM; Chiang JM; Lee CF; Yu MC; Lee WC; Chen JS; Wang JY
    World J Surg Oncol; 2011 Dec; 9():174. PubMed ID: 22208884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consequences of chemotherapy on resection of colorectal liver metastases.
    Pessaux P; Chenard MP; Bachellier P; Jaeck D
    J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
    Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C
    Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
    Yoshita H; Hosokawa A; Ueda A; Ando T; Kajiura S; Kato H; Kawabe H; Tomizawa G; Horikawa N; Yabuhita K; Note M; Sugiyama T
    Digestion; 2014; 89(1):43-8. PubMed ID: 24458112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
    de Haas RJ; Wicherts DA; Flores E; Ducreux M; Lévi F; Paule B; Azoulay D; Castaing D; Lemoine A; Adam R
    Ann Surg Oncol; 2010 Apr; 17(4):1010-23. PubMed ID: 20052553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.
    Zimmitti G; Shindoh J; Mise Y; Kopetz S; Loyer EM; Andreou A; Cooper AB; Kaur H; Aloia TA; Maru DM; Vauthey JN
    Ann Surg Oncol; 2015 Mar; 22(3):834-842. PubMed ID: 25227306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases.
    Zorzi D; Chun YS; Madoff DC; Abdalla EK; Vauthey JN
    Ann Surg Oncol; 2008 Oct; 15(10):2765-72. PubMed ID: 18636296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
    Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
    Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
    Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
    Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
    J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
    Wicherts DA; de Haas RJ; Sebagh M; Ciacio O; Lévi F; Paule B; Giacchetti S; Guettier C; Azoulay D; Castaing D; Adam R
    Ann Surg Oncol; 2011 Mar; 18(3):659-69. PubMed ID: 20976564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.
    Thomay AA; Nagorney DM; Cohen SJ; Sigurdson ER; Truty MJ; Burtness B; Hall MJ; Chun YS
    J Gastrointest Surg; 2014 Jan; 18(1):69-74. PubMed ID: 24002765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.